Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Canadian Supreme Court Rules Pfizer’s Viagra Patent Is Invalid

By Pharmaceutical Processing | November 9, 2012

In a 7-0 decision, the Supreme Court of Canada ruled Thursday that Pfizer’s patent on Viagra (sildenafil) is invalid following a legal challenge by Teva. Pfizer said it expects the erectile dysfunction drug “to face generic competition in Canada shortly,” adding that it was disappointed with the decision.

Teva first challenged the patent in 2007, arguing that Pfizer did not disclose Viagra’s active ingredient among a large number of compounds listed in the patent. However, a lower court issued a decision in 2009, upholding Pfizer’s patent, which was originally scheduled to expire in 2014. In the latest ruling, the Supreme Court determined that “Pfizer had the information needed to disclose the useful compound and chose not to release it. Even though Pfizer knew that the effective compound was sildenafil at the time it filed the application, it limited its description.”

“Pfizer gained a benefit from the act — exclusive monopoly rights — while withholding disclosure,” Justice Louis LeBel noted, adding that “as a matter of policy and sound statutory interpretation, patentees cannot be allowed to ‘game’ the system in this way. This, in my view, is the key issue in this appeal.” The court’s decision will apply to any patent application in Canada.

A U.S. court ruled last year that Teva could not launch a generic version of Viagra in the country until 2019.

 

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards